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Abstract
Background: Randomized clinical trials (RCTs) stopped early for benefit often receive great
attention and affect clinical practice, but pose interpretational challenges for clinicians, researchers,
and policy makers. Because the decision to stop the trial may arise from catching the treatment
effect at a random high, truncated RCTs (tRCTs) may overestimate the true treatment effect. The
Study Of Trial Policy Of Interim Truncation (STOPIT-1), which systematically reviewed the
epidemiology and reporting quality of tRCTs, found that such trials are becoming more common,
but that reporting of stopping rules and decisions were often deficient. Most importantly,
treatment effects were often implausibly large and inversely related to the number of the events
accrued. The aim of STOPIT-2 is to determine the magnitude and determinants of possible bias
introduced by stopping RCTs early for benefit.
Methods/Design: We will use sensitive strategies to search for systematic reviews addressing the
same clinical question as each of the tRCTs identified in STOPIT-1 and in a subsequent literature
search. We will check all RCTs included in each systematic review to determine their similarity to
the index tRCT in terms of participants, interventions, and outcome definition, and conduct new
meta-analyses addressing the outcome that led to early termination of the tRCT. For each pair of
tRCT and systematic review of corresponding non-tRCTs we will estimate the ratio of relative
risks, and hence estimate the degree of bias. We will use hierarchical multivariable regression to
determine the factors associated with the magnitude of this ratio. Factors explored will include the
presence and quality of a stopping rule, the methodological quality of the trials, and the number of
total events that had occurred at the time of truncation.
Finally, we will evaluate whether Bayesian methods using conservative informative priors to
"regress to the mean" overoptimistic tRCTs can correct observed biases.
Discussion: A better understanding of the extent to which tRCTs exaggerate treatment effects
and of the factors associated with the magnitude of this bias can optimize trial design and data
monitoring charters, and may aid in the interpretation of the results from trials stopped early for
benefit.
Background
Interim analyses conducted early in the course of a rand-
omized clinical trial (RCTs) may suggest larger than
expected treatment effects that are inconsistent with
chance. Consequently, investigators and data monitoring
committees may conclude that one treatment is superior
to the other and decide to stop the trial and release the
results, arguing that completing the trial as planned is
unadvisable or even unethical. The publicity surrounding
such action often captures considerable attention because
of the large treatment effects and the dramatic nature of
the decision to terminate early.
Clinicians, authors of systematic reviews and meta-analy-
ses, and professional organizations issuing recommenda-
tions face challenges when interpreting the results of such
Published: 6 July 2009
Trials 2009, 10:49 doi:10.1186/1745-6215-10-49
Received: 11 February 2009
Accepted: 6 July 2009
This article is available from: http://www.trialsjournal.com/content/10/1/49
© 2009 Briel et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 2 of 10
(page number not for citation purposes)
Trials 2009, 10:49 http://www.trialsjournal.com/content/10/1/49truncated RCTs (tRCTs), because the results could be
overly optimistic. Bias arises because random fluctuations
towards greater treatment effects may result in early termi-
nation[1] In other words, the estimated treatment effect
may be exaggerated because statistical stopping rules are
prone to stop a trial at a random high. If the decision to
stop the trial resulted from observing the apparent benefit
of treatment at a random high, the resulting estimate of
the treatment effect will be misleadingly large. If this
occurs, data from future similar trials would be expected
to yield a smaller estimate of treatment effect, as a conse-
quence of the so-called "regression to the (true) mean"
effect[2]
A systematic review of 143 RCTs stopped early for benefit,
the Study Of Trial Policy Of Interim Truncation (STO-
PIT)-1, was published in 2005[3] This systematic review
documented a recent doubling in the number of tRCTs
and found that tRCTs are often published in high profile
medical journals. The reporting of the methods that
informed the decision to truncate the trials was often defi-
cient, and treatment effects were often implausibly large,
especially when the number of events was small. A recent
review focusing on oncology trials stopped early for ben-
efit raised further concerns, finding that almost 80% of
tRCTs published in the last three years were used to attain
regulatory approval[4]
The extent to which tRCTs actually overestimate effects,
the magnitude of bias, and the factors associated (and per-
haps causally related) with the magnitude of bias in indi-
vidual situations, remain uncertain. If one could identify
a comprehensive set of trials not stopped early that
addressed the same question as a tRCT, those trials or all
trials (including the tRCT) could provide a least biased
assessment of the true treatment effect that the corre-
sponding tRCT (or tRCTs if there were more than one
addressing the same question) was trying to estimate. The
goal of this project is to obtain such a comprehensive set
of trials matching a number of tRCTs, and thus address
the question of magnitude of bias, and variables associ-
ated with the magnitude of bias.
Study objectives
The present study, STOPIT-2, seeks to determine the mag-
nitude and determinants of bias that truncation of RCTs
for benefit may introduce. Our primary research questions
are:
• What is the extent to which tRCTs overestimate the treatment
effect compared with the best available estimate of treatment
effect as determined by a systematic review and meta-analysis
of RCTs addressing the same question as the tRCT?
• What factors are associated with the size of the observed dif-
ference in the treatment effect between the tRCT and the
respective meta-analytic estimate?
• Can Bayesian methods, using conservative priors, provide
more likely estimates of the true underlying treatment effect,
i.e. somehow "correct" for truncation bias?
Methods
Overview of methods
STOPIT-1 included 143 tRCTs and we were able to iden-
tify 14 additional RCTs stopped early for benefit through
a hand search in the medical literature and personal con-
tact with trial investigators. The effort to identify tRCTs
will continue by updating the search that led to the trials
identified for STOPIT-1 (November 2004) using the same
search strategy and through citation searching linked to
the STOPIT-1 publication and accompanying editorial in
JAMA[3,5]
In STOPIT-2, we will search for systematic reviews
addressing the same question as the tRCTs (Figure 1). We
will utilize the sensitive strategy for systematic reviews put
forth for MEDLINE by Montori et al[6] Systematic reviews
that ask a similar question to the tRCT but do not include
the tRCT due to its publication after the search date of the
systematic reviews will be updated to the present time.
Other systematic reviews that include the tRCT will not be
updated. Systematic reviews that are only similar under
the broadest of definitions will be included only if the
review authors chose to pool the tRCT within the system-
atic review.
From each eligible systematic review we will blind each
RCT's results and two independent reviewers will deter-
mine eligibility. From each eligible trial we will then
extract data and conduct new meta-analyses addressing
the outcome that led to the early termination of the
tRCT(s). First, we will compare the relative risk generated
by the tRCT with the relative risk from all non-truncated
studies. Second we will use multivariable regression to
determine the factors associated with the difference in
magnitude of effect between the tRCTs and RCTs not
stopped early. These factors will include the presence and
quality of a stopping rule, the methodological quality of
the trials, and the number of events that had occurred at
the time of truncation. Finally, we will compare possible
methods for correcting the treatment effect estimates from
tRCTs, in particular the use of Bayesian methods using
conservative informative priors to "regress to the mean"
the tRCT estimates. We will then compare the degree of
disagreement with the meta-analytical estimates between
the Bayesian-adjusted tRCT and the unadjusted tRCT
results.Page 3 of 10
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non-truncated trials addressing the same question will
yield minimally biased estimates of treatment effects[7,8]
However, our previous empirical finding that stopped-
early studies contributed more than 40% of the weight in
more than a third of meta-analyses including tRCTs chal-
lenges this view[9]) Nevertheless, if the overall estimate of
treatment effect (based on all studies, including tRCTs)
were the least biased estimate of the true underlying effect,
it is this estimate to which one should compare tRCTs.
Based on simulations and theoretical considerations we
found compelling strengths and compelling limitations
for each approach (Table 1). We will explore the extent to
which results are consistent with the hypothesis that the
pooled estimate including the tRCTs is least biased using
our empirical data (for instance, the tRCTs should provide
Flow chart of the Study of Trial Policy of Interim Truncation (STOPIT)-2igure 1
Flow chart of the Study of Trial Policy of Interim Truncation (STOPIT)-2. Abbreviations: RCT, randomized clinical 
trial; tRCT, truncated randomized trial due to stopping early for benefit; PICO, patient population, intervention, control, out-
come.
Table 1: Comparison of non-truncated RCTs only and truncated + non-truncated RCTs as comparators to estimate the magnitude of 
bias associated with stopping clinical trials early for benefit based on simulations and theoretical considerations.
Non-truncated RCTs only Truncated & non-truncated RCTs
- more appropriate when the number of non-truncated RCTs in meta-
analyses is relatively small 
(= weight of tRCTs in meta-analyses relatively large)
- more appropriate when the number of non-truncated RCTs in meta-
analyses is relatively large 
(= weight of tRCTs in meta-analyses relatively small)
- more appropriate when true treatment effects are small 
(RCTs in meta-analyses likely to be underpowered)
- more appropriate when true treatment effects are large 
(RCTs in meta-analyses likely to be adequately powered)
- more appropriate in the presence of considerable publication bias - more conservative bias estimation
- more appropriate when proportion of trials in meta-analyses without 
formal stopping rule is large
- trial sample separate/independent from tRCT(s) facilitates statistical 
analysis
Abbreviations: RCTs, randomized clinical trials; tRCT(s), truncated randomized clinical trial(s) due to stopping early for benefitPage 4 of 10
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their having fewer events because of stopping early).
Choosing a primary analysis for a study commonly
involves some arbitrariness. Given compelling reasons for
either approach, we decided to conduct both analyses. We
chose non-truncated RCTs only as the comparator in our
primary analysis. In a complementary second analysis, we
will compare the tRCT and the pooled estimate of all trials
including the tRCT.
Literature Search for Systematic Reviews
For meta-analyses, we will search the Cochrane Database
of Systematic Reviews and the Database of Abstracts of
Reviews of Effects using the population and intervention
of the tRCTs as search terms. We will also search for meta-
analyses in MEDLINE with textwords and Medical Subject
Heading terms based on the study population and the
intervention specified in the research question of the
tRCTs, if necessary supplemented by a specified outcome,
and with textwords "meta-analysis" OR "overview" OR
"systematic review" and in a second approach with limits
"meta-analysis.pt." AND "human"[6]
Eligibility of Systematic Reviews
Systematic reviews will be considered eligible if they meet
all of the following 5 criteria:
1) Report the methods used to conduct the review
2) Describe a literature search that, at minimum, includes
MEDLINE
3) Include a population similar to that of the tRCT
4) Include an intervention similar to that of the tRCT
5) Include an outcome similar to the one that was the
basis of the decision to stop the tRCT early
Because there is considerable judgment involved in the
eligibility decisions, particularly criteria 3 to 5, every deci-
sion of the initial adjudicators will be reviewed and con-
firmed or refuted by another adjudicator and if necessary,
by a third party. If in doubt while applying the broadest
similarity criteria, a key factor for eligibility will be that
the systematic review pooled the tRCT. In general, if in
doubt, we will judge the systematic review eligible,
because there will be a second review of eligibility at the
level of individual trials.
Updating of Systematic Reviews
The only systematic reviews we will update are those that
did not include the index tRCT(s) because they were com-
pleted prior to the publication of the tRCT. In these
instances, we will update the search of the systematic
reviews to the present using the same strategy used in the
systematic review. We will not update all meta-analyses in
the systematic reviews, only the ones for the outcomes
that led to the early termination of the matching tRCT(s).
Identification, retrieval and eligibility of RCTs included in 
the systematic reviews
For each systematic review we will retrieve all included
RCTs in full text (including associated manuscripts
describing methods) to determine their similarity to the
index tRCT. We will obtain data from unpublished studies
that were included in the systematic reviews by contacting
the authors of the systematic review and/or the authors of
the unpublished studies. Including trials addressing a
question that was different to that addressed in the rele-
vant tRCT would bias the assessment of magnitude of
effect from the trials not stopped early. Thus, we will judge
the eligibility of each trial in the systematic review on the
basis of the following criteria:
1) Including a population similar to that of the tRCT
2) Including an intervention similar to that of the tRCT
3) Including a control similar to that of the tRCT
4) Including an outcome similar to the one that led to the
early termination of the tRCT
5) Random allocation to intervention and control group
One could have criteria for similarity that are very strict, or
very permissive. As it is uncertain what the right approach
is, we will classify the population, intervention, control
and outcome of each potentially eligible trial as either
"more or less identical", "similar, but not identical" or
"broadly similar". The eligibility form will allow differen-
tiation between eligibility of the studies based on the nar-
row, the broad or the broadest criteria and the "closeness"
of the RCTs to the index tRCT will be considered in the
analyses. We will construct a number of teams of two
reviewers to make the eligibility decisions.
Each team will include individuals with expertise relevant
to the content of the studies they will review. Within each
pair of reviewers, the rating of the individual RCTs will be
done independently and in duplicate. Disagreements will
be resolved by discussion and, if necessary, by a third
party. Because we are at risk of bias in the decision about
whether to include a RCT based on the results, the review-
ers who judge eligibility will be blinded to the results of
the trial. Blinding will be accomplished by a separate
team, not involved in study selection, using black ink on
"hard copies" before these are scanned into electronic for-
mat or using black boxes overlaid on the sections describ-Page 5 of 10
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format of the paper. Every section of potentially eligible
RCTs that reports the magnitude of results (abstract,
results and discussion) will be blinded before the decision
on eligibility is made. Blinding will be tested in a random
set of 20 papers sent to 20 reviewers to ensure its success.
For RCTs, disagreements in relation to similarity of 2 lev-
els or greater will require adjudication. Disagreements in
relation to similarity of 1 level will not and the broader
similarity rating will be assumed correct (Figure 2).
Data extraction
From each RCT, we will collect the following data in
duplicate.
1. Stopped early (yes/no)
2. Methodological quality: allocation concealment (docu-
mented as central independent randomization facility or
numbered/coded medication containers prepared and
distributed by an independent facility (e.g. pharmacy));
blinding of participants, care providers, and outcome
adjudicators (blinding of participants and care providers
will be rated as "probably yes" when trial report states
"double blinded" or "placebo controlled"); loss to follow-
up (we will collect the number of participants rand-
omized and the number of participants with outcome
data for the outcome of interest allowing for an estima-
tion of loss to follow-up)
3. Measure of treatment effect for the outcome that termi-
nated the tRCT (events and number randomized in inter-
vention and control groups)
4. Pre-implemented stopping characteristics, if any (e.g.,
planned sample size, interim looks, stopping rules,
number of events)
5. Date of conduct of the trial (start date, stop date, publi-
cation date)
Statistical Analysis
We will calculate relative risks for each RCT in our study.
For studies that provide results as continuous data
(means, standard deviations), we will estimate an approx-
imate dichotomous equivalent. To do this we will assume
normal distributions of the results and that half a stand-
ard deviation represents the minimal important
change[10] Using baseline data we will obtain the 0.5
standard deviation threshold from the baseline distribu-
tion and calculate the proportion of each follow-up distri-
bution above or below (depending on the direction of the
outcome) the threshold, i.e. the proportion of patients in
each treatment arm who "did worse". This will allow us to
specify relative risks and associated confidence intervals. If
baseline data are not available, we will use the follow-up
distribution of the control group to substitute for the 0.5
standard deviation threshold.
As well, for each meta-analysis we will calculate the
pooled relative risk and 95% confidence interval for all tri-
als that were not stopped early. Where there is more than
one tRCT per meta-analysis we will also calculate a pooled
relative risk and confidence interval for those tRCTs. These
pooled estimates of relative risks will be calculated using
an inverse variance weighted random effects model.
We will graphically present the results in a scatterplot of
the effect size (relative risk) of the tRCT (horizontal axis)
against the pooled effect size of non-tRCTs (vertical axis).
If the tRCT and non-tRCTs give similar results, the points
Example to illustrate the process of judging similarity between a randomized clinical trial and the corresponding truncated ran-domized clinical trialFigur  2
Example to illustrate the process of judging similarity between a randomized clinical trial and the correspond-
ing truncated randomized clinical trial. Level 1 = Meets narrow criteria; Level 2 = Meets broad criteria; Level 3 = Meets 
broadest criteria; Level 4 = Does not meet criteria. * For differences in reviewer ratings of 1 level we will consider the broader 
similarity rating for the overall rating. ** Differences in reviewer ratings of 2 levels or greater will require adjudication by a 
third reviewer.
Category Rating Reviewer 1 Rating Reviewer 2 Overall Rating
Patients Level 2 Level 1          Level 2*
Intervention Level 1 Level 3   Adjudication**
Control Level 2 Level 4   Adjudication**
Outcome Level 1 Level 1          Level 1 Page 6 of 10
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if the tRCTs overestimate treatment effects they should be
found above the diagonal.
We will also perform a z-test for each meta-analysis to
look for differences between the truncated and non-trun-
cated RCTs for the pooled relative risks. As a summary
measure we will calculate a ratio of relative risks for each
meta-analysis as follows:
We will plot the log(ratio of relative risks) and calculate an
overall log(ratio of relative risks) as an inverse variance-
weighted average of the log(ratio of relative risks). These
will be back transformed and the ratio of relative risk val-
ues will be plotted for presentational purposes.
To investigate possible predictors of treatment effect sizes
in RCTs, we will perform a hierarchical (multi-level)
regression analysis. Our model will have two levels: indi-
vidual RCT (study) level and meta-analysis level. The
dependent variable in this analysis will be the logarithm
of the relative risk (logRR) for each study and we will
investigate the associations of the logRR with characteris-
tics of the individual studies. We will investigate five pos-
sible predictors. Our main predictor of interest is a
variable that we will construct from two different study
characteristics, the presence and quality of a stopping rule
and whether or not the RCT was truncated early.
The rule for stopping early will be categorized as one of
three possibilities: (i) a rigorous rule (published prior to
the trial plan), (ii) a not-so-rigorous rule such as ad hoc
rules developed during the trial, (iii) no rule or unknown.
Each of these three possibilities will be combined with
whether or not the trial stopped early, creating 6 catego-
ries in total. It is very likely that there will be less than six
categories in our final analysis as it is quite conceivable
that some of the scenarios will not occur. We will carry out
post hoc comparisons of outcomes between these 6 groups,
focusing on contrasts that highlight the effects of the rule
and the "truncated study" variable, and their interaction,
to the extent that the available data permit.
Other study-level characteristics that we will examine are
the methodological quality (blinding of patients, care-giv-
ers, and outcome assessors, and allocation concealment),
and the total number of events. At the meta-analysis level,
the only variable in the model will be an indicator of the
specific meta-analyses to which each study belongs.
We will look at the main effects of all the variables and the
interaction between the rule/truncated variable and the
other predictor variables. Each study will yield a summary
statistic (logRR) and an associated variance. The variance
will provide weights for a meta-regression to evaluate the
determinants of the estimated treatment effect.
The multivariable regression described above will be per-
formed on 5 different datasets based on different levels of
a variable which we will call closeness. This variable will
measure how similar the non-truncated trials in each
meta-analysis are to the corresponding truncated trial(s)
with regard to the a) patient population, b) treatment
arm, c) control arm and d) outcome. For each of these
four, we will categorize closeness into one of three levels:
very close (termed as 'fits the narrow criteria' in the data-
base), moderately close (termed as 'fits the broad criteria'
in the database), and less close (termed as 'fits the broad-
est criteria' in the database). This judgement will be coded
by 2 reviewers, and the level of agreement (kappa)
checked. Each trial will then be categorized by its least
close category over the four areas which we will use to
define our 5 different datasets. The datasets will be: 1)
only trials that are "very close" in all domains; 2) trials
with one or more "moderately close" domain, but no "less
close" domains and not "very close" in all domains; 3) tri-
als that are "less close" in at least one domain; 4) trials
that are "very close" or "moderately close" in all domains
(corresponds to 1) and 2) combined); and 5) all trials.
As discussed previously, we will conduct a further analysis
in which the comparison is between the tRCT and the
pooled estimate of all trials including the tRCT. If the
tRCTs provide relatively small weights in the meta-analy-
ses as a result of fewer events because of stopping early,
the pooled estimate including the tRCTs may provide the
least biased summary estimate.
Finally, we will compare possible methods for correcting
the estimates from tRCTs for possible bias, in particular
the use of Bayesian methods. The basic approach here is
to use a conservative prior for trials (derived empirically
from past trials in other areas – we will review such exist-
ing reviews [11-13]) and combine this information with
the data from the tRCT to obtain a posterior estimate of
effect. The weight will depend on the relative variance of
the conservative prior and the tRCT: small trials will lead
to an emphasis on the conservative prior whereas large tri-
als will attach relatively greater importance to the
observed data. We will calculate such Bayesian relative
risks for each tRCT in our study. As for the simple tRCT
estimate, we will graphically present the results for a visual
comparison of the effect size (relative risk) of the trun-
cated RCT(s) and the non-truncated RCTs. Based on pre-
vious simulation work [14] we would predict that the
Bayesian estimates obtained will be closer to the meta-
analysis findings.
log( ) log( /ratio of relative risks relative risk of tRCT rel= ative risk of pooled non tRCTs
relative risk of tRCT
− =)
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The results of STOPIT-2 will extend earlier modeling stud-
ies and a systematic review of trials stopped early to pro-
vide a precise estimate of the extent of that bias as it plays
out in the real world. Estimating the extent of bias and fac-
tors associated with the magnitude of bias will have impli-
cations for the design, conduct, and reporting of future
clinical trials.
Strengths and limitations of our protocol
Strengths of our study protocol include a systematic and
extensive literature search with the goal of compiling a
comprehensive sample of RCTs stopped early for benefit.
Notwithstanding, despite complementing our electronic
literature search of multiple databases with hand searches
and personal contacts, we may fail to identify relevant
tRCTs as truncation is often not explicitly stated in trial
abstracts or methods[15]
We will use sensitive search strategies to identify system-
atic reviews corresponding to tRCTs,[6] and will under-
take a labor-intensive process of judging eligibility of
several thousand individual RCTs, each being assessed
independently by two reviewers blinded to the RCT
results. The blinding of trials prior to review is a particular
strength of this study, limiting the potential for biased eli-
gibility assessment on the basis of the magnitude of effect
of the studies.
The accuracy of our results depends on the comprehensive
search of the systematic reviews we will include. We have
set a relatively low threshold for inclusion of correspond-
ing systematic reviews: that the review included a meth-
ods section and that the systematic search included at least
MEDLINE. Publication bias threatens all systematic
reviews, and many do not include a thorough search for
unpublished trials. To the extent that publication bias
exists, however, it will likely lead to overestimates of the
effects found in the pooled non-truncated RCTs. We
assume that publication bias is less likely to affect the
tRCTs. Thus, we anticipate that publication bias will yield
an underestimate of the upward bias of the tRCTs relative
to the non-tRCTs, and hence that our estimate of bias
associated with truncation is likely to be conservative.
Despite objective criteria, when assessing the methodo-
logical quality of RCTs we are limited by the quality of the
reporting of the trials.
A further strength of the study is the planned hierarchical
analysis in which we link the estimates of treatment effect
from tRCTs and non-tRCTs addressing the same question.
Since the extent to which studies address the same ques-
tion is a matter of judgment, the provision for a sensitivity
analysis based on similarity of question will further
strengthen the results.
Ethical and data monitoring implications
The results of this study may have a profound effect on the
decision-making of data monitoring committees[16] Data
monitoring committees have an ethical obligation to
ensure patients are offered effective treatment as soon as it
is clear that an effective treatment is indeed available. To
many people, this mandates a stopping rule that will
ensure that any trial that shows an apparently large treat-
ment effect at an early stage does not continue beyond a
certain point. Data monitoring committees also have,
however, an ethical obligation to future patients,[14] who
require precise and accurate data addressing patient-
important outcomes to make optimal treatment choices.
While there is growing awareness that stopping trials early
for apparent benefit may lead to overestimated
results,[17] little is known about the magnitude and the
determinants of bias that truncation introduces. The
results of STOPIT-2 will provide valuable guidance to
investigators, institutional review boards, funding agen-
cies, and data monitoring committees regarding appropri-
ate use of stopping rules in clinical trials.
Public Engagement in Science
The results of STOPIT-2 will impact on numerous issues of
public interest. Investigators, patients and their advocates,
institutional review boards, and funding agencies may
have different but convergent interests in stopping a study
as soon as an important difference between experimental
and control group emerges. Increased impact and public-
ity may motivate investigators, journals, and funding
agents. A commitment to promptly offer participants in
the less favorable arm the better treatment choice may
motivate investigators, patients and their advocates, and
data monitoring committees. The opportunity to save
research dollars by truncating a trial may motivate the
funding agencies.
Although a recent extension to the CONSORT statement
for abstracts highlights the importance of reporting if the
trial has stopped earlier than planned and the reason for
doing so,[18] a number of observations suggest that inves-
tigators, journal editors, and clinical experts remain
mostly unaware of the problematic inferences that may
arise from truncated RCTs. Top journals continue to pub-
lish results of stopped early trials, but fail to require
authors to note the early stopping in the abstract and to
report details that would allow readers to carefully evalu-
ate the decision to stop early[3] The QUOROM guidelines
for meta-analyses and systematic reviews of RCTs [19] rec-
ommend that authors describe potential biases in the
review process, but systematic reviewers pay scant atten-
tion to the potential bias introduced by including in theirPage 8 of 10
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Important professional organizations continue to issue
recommendations on the basis of trials stopped early for
benefit, including those that had reported very few end-
points and which therefore seem most likely to overesti-
mate effects[20,21]
Empirical evidence of the magnitude and determinants of
bias that truncation introduces will ensure that investiga-
tors, editors, authors of meta-analyses and guideline pan-
els become appropriately cautious in their interpretation
of stopped early trials. Ultimately, this will reduce the risk
of prematurely translating unreliable study findings into
clinical practice.
The findings of STOPIT-2 will influence recommenda-
tions on how to design and conduct RCTs and meta-anal-
yses, and how to report their results, as summarized in the
CONSORT [22] and QUOROM [19] guidelines. The
results of the proposed study will also have implications
for systematic reviews, including those who publish in the
Cochrane Library. Grading the strength of recommenda-
tions and quality of evidence in clinical guidelines will
also be influenced by the findings of STOPIT-2[23] Given
the increasing frequency with which trials are stopped
early, the results of STOPIT-2 will be of interest to numer-
ous stakeholders including patients and their physicians,
investigators, research ethics boards, funding agencies,
journal editors, and policy makers.
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